"
Team:Paris Bettencourt/Project/Overview
From 2013.igem.org
Ewintermute (Talk | contribs) |
Zmarinkovic (Talk | contribs) |
||
| (30 intermediate revisions not shown) | |||
| Line 1: | Line 1: | ||
| - | {{:Team:Paris_Bettencourt/ | + | {{:Team:Paris_Bettencourt/Wiki}} |
| + | {{:Team:Paris_Bettencourt/Menu}} | ||
<html> | <html> | ||
| + | <div style="width:1100px;margin:0 auto;"> | ||
| + | <img src="https://static.igem.org/mediawiki/2013/3/3a/PB_logoParis.gif" width="122px" style="position:absolute;top:40px;right:30px;"/> | ||
| + | </div> | ||
| + | |||
| + | <link href='http://fonts.googleapis.com/css?family=Great+Vibes' rel='stylesheet' type='text/css'> | ||
| + | <img src="https://static.igem.org/mediawiki/2013/d/da/PB_banneroverviewProjects.png"/> | ||
<style> | <style> | ||
.titletile { | .titletile { | ||
| Line 16: | Line 23: | ||
height:300px; | height:300px; | ||
margin-bottom:15px; | margin-bottom:15px; | ||
| + | } | ||
| + | .factstile { | ||
| + | background:rgb(252,250,229); | ||
| + | width:100%; | ||
| + | height:73px; | ||
| + | margin-bottom:15px; | ||
| + | font-size:2em; | ||
| + | line-height:73px; | ||
| + | text-align:center; | ||
| + | font-weight:normal; | ||
| + | } | ||
| + | .factstile a:hover { | ||
| + | font-weight:bold; | ||
| + | } | ||
| + | .factstile a { | ||
| + | color: rgb(30,39,43); | ||
} | } | ||
.leftparagraph { | .leftparagraph { | ||
| Line 33: | Line 56: | ||
background:rgb(252,250,229); | background:rgb(252,250,229); | ||
overflow:hidden; | overflow:hidden; | ||
| + | margin-bottom:15px; | ||
} | } | ||
.projtile h2 { | .projtile h2 { | ||
| Line 48: | Line 72: | ||
margin-right:5%; | margin-right:5%; | ||
font-size:17px; | font-size:17px; | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
} | } | ||
</style> | </style> | ||
| Line 64: | Line 82: | ||
<div class="abstractile"> | <div class="abstractile"> | ||
<div class="leftparagraph"> | <div class="leftparagraph"> | ||
| + | <center><img src="https://static.igem.org/mediawiki/2013/d/d1/PB_overview2project.png" width="380"/></center> | ||
</div> | </div> | ||
<div class="rightparagraph"> | <div class="rightparagraph"> | ||
<p> | <p> | ||
| - | To defeat tuberculosis, we need new biotechnology. Our work | + | To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. <b>Detect</b> - a CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. <b>Target</b> - an <i>E. coli</i> model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. <b>Infiltrate</b> - an <i>E. coli</i> strain capable of entering infected macrophages and lysing mycobacteria. <b>Sabotage</b> - a non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance. |
</p> | </p> | ||
</div> | </div> | ||
| Line 78: | Line 97: | ||
</a> | </a> | ||
<p> | <p> | ||
| + | Diagnosing antibiotic resistance can improve and accelerate treatment. We propose a phage-delivered, CRISPR-based system that cuts specific DNA sequences and detects the presence of resistance genes due to the resulting DNA damage that is reported with a color output. | ||
| + | |||
</p> | </p> | ||
</div> | </div> | ||
| Line 87: | Line 108: | ||
<p> | <p> | ||
| - | <i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where | + | <i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where it is easy to screen for targeted small-molecule inhibitors. |
</p> | </p> | ||
| Line 98: | Line 119: | ||
<p> | <p> | ||
| - | An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, <i>E. coli</i> express | + | An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, <i>E. coli</i> express listeriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane. |
</p> | </p> | ||
| Line 112: | Line 133: | ||
</div> | </div> | ||
<div style="clear: both;"></div> | <div style="clear: both;"></div> | ||
| - | <div class=" | + | <div class="factstile"> |
| + | <a href="https://2013.igem.org/Team:Paris_Bettencourt/Human_Practice/TB_Facts">TB Facts: what you need to know about TB.</a> | ||
</div> | </div> | ||
| - | + | </a> | |
</div> | </div> | ||
<div style="clear: both;"></div> | <div style="clear: both;"></div> | ||
</html> | </html> | ||
{{:Team:Paris_Bettencourt/footer}} | {{:Team:Paris_Bettencourt/footer}} | ||
Latest revision as of 00:27, 29 October 2013
To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. Detect - a CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. Target - an E. coli model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. Infiltrate - an E. coli strain capable of entering infected macrophages and lysing mycobacteria. Sabotage - a non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance.
Detect
Diagnosing antibiotic resistance can improve and accelerate treatment. We propose a phage-delivered, CRISPR-based system that cuts specific DNA sequences and detects the presence of resistance genes due to the resulting DNA damage that is reported with a color output.
Target
M. tuberculosis grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to E. coli, where it is easy to screen for targeted small-molecule inhibitors.
Infiltrate
An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, E. coli express listeriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane.
Sabotage
Totally drug-resistant TB (TDR-TB) is an established and growing problem. We have created a phage vector that delivers an siRNA capable of sabotaging drug resistance and restoring sensitivity. By reducing the fitness burden of our construct, we can promote its spread in a population.
+33 1 44 41 25 22/25
team2013@igem-paris.org 
